Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the safety and tolerability of oral dose of
selumetinib in combination with chemotherapies (cisplatin and gemcitabine) in Japanese
patients with advanced biliary tract cancer (BTC). In addition, the pharmacokinetic (PK)
profile of selumetinib and chemotherapies will be investigated. Also, the Maximum tolerated
dose (MTD) of selumetinib in combination with chemotherapies for Japanese BTC patients will
be identified, if possible.